Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Revista
País de afiliación
Intervalo de año de publicación
1.
AIDS ; 20(12): 1621-6, 2006 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-16868443

RESUMEN

BACKGROUND: Hypersensitivity reaction to nevirapine, which in some cases can be fatal, shows a higher prevalence in Sardinia in comparison with other Italian regions. OBJECTIVE: This study demonstrates that hypersensitive reaction to nevirapine in Sardinian HIV-infected patients is associated with the HLA Cw8-B14 haplotype. These two HLA class I antigens are in strong linkage disequilibrium in the Sardinian population. METHODS: Forty-nine Sardinian HIV-positive patients treated with nevirapine were studied. Thirteen (26%), developed a hypersensitive reaction thus requiring the drug to be discontinued. HLA class I and II molecular typing was performed in both nevirapine-hypersensitive and nevirapine-tolerant patients. To avoid biased representation of the allele frequencies in the two groups of treated patients, molecular typing was also performed in 82 HIV-positive patients who had not been treated with nevirapine. RESULTS: Considerable overlap was observed for the clinical, immunological and demographic characteristics of the 13 hypersensitive patients and 36 tolerant patients. Clinical parameters included viral load, status of HIV infection, CD4 and CD8 cell counts, hepatitis C virus/hepatitis B virus co-infections. Forty-six percent (6/13) of the nevirapine-hypersensitive subjects had the HLA-Cw8 and HLA-B14(65) antigens compared with 5% (2/36) of the nevirapine-tolerant group (P = 0.004; Pc = 0.05). CONCLUSION: In agreement with other recent reports, the utility of HLA typing in HIV patients to identify genetic factors that may confer susceptibility to drug-induced hypersensitive reaction was confirmed. A careful choice of antiretroviral therapy in susceptible individuals should significantly reduce the risk of severe hypersensitive reaction.


Asunto(s)
Hipersensibilidad a las Drogas/inmunología , Infecciones por VIH/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Nevirapina/efectos adversos , Inhibidores de la Transcriptasa Inversa/efectos adversos , Adolescente , Adulto , Hipersensibilidad a las Drogas/epidemiología , Hipersensibilidad a las Drogas/etiología , Femenino , Frecuencia de los Genes , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Antígenos HLA-B/inmunología , Antígeno HLA-B14 , Antígenos HLA-C/inmunología , Antígenos HLA-DR/inmunología , Haplotipos , Hepatitis C/complicaciones , Hepatitis C/inmunología , Humanos , Italia/epidemiología , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Nevirapina/inmunología , Prevalencia , Inhibidores de la Transcriptasa Inversa/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA